Journal of Integral Sciences

RAIL-GUIDED MAGNETIC ADHESION FOR SLIPPAGE MITIGATION IN WALL-CLIMBING ROBOTS

Josephine Jovinus Didas, Li Rui — Sun, 15 Feb 2026 00:00:00 -0500

Wall-climbing robots have a great deal of potential for checking, repairing and guarding vertical and inverted areas. Mostly of these robots faced challenges in slippage, mainly when they go over uneven or inclined walls. A new method is offered in this paper that combines rail tracking, magnetic adhesion of wheels and supporting inner tires to make sure wall climbing robots do not slip. The arrangement of joints makes it possible for the wheels to remain stable, have a better grip and make adjustments for carrying weight. There is a two-layered mechanism in the methodology where outer magnetic wheels stick to the steel rails while inner wheels are kept in the center and have constant contact by springs. Motor movement is controlled by a microcontroller and use Bluetooth to control the car remotely. Adhesion force, traction torque, relevant slippage measures and the required power were studied using different mathematical models. The models used to describe load balance, magnetic attraction and the movement of the plate during loading were all checked by running simulations in MATLAB, Solidworks and ANSYS. The prototype was constructed using fiber-reinforced plastic for car body, wheels which have permanent magnets and was tried out on surfaces that were horizontal, inclined and vertical. Results showed increased stability while moving horizontally and vertically, fewer accidents due to slipping and good load support. Rail-track designs offer a better, simpler and stronger way compared to adhesion approaches like suction and bio-adhesive systems. This research provides a useful way of moving in robotics that joins theory, making and usefulness in the real world

FORMULATION AND EVALUATION OF A NATURAL EXCIPIENT–BASED ANTIFUNGAL GEL CONTAINING CLOTRIMAZOLE FOR TOPICAL APPLICATION

Sushma K, Rajender Reddy Karnekanti, Teja Kumar Reddy Konatham — Sat, 21 Feb 2026 00:00:00 -0500

Clotrimazole is a widely used imidazole antifungal agent effective against dermatophytes, yeasts, and molds; however, conventional topical formulations often suffer from poor patient compliance and limited residence time at the site of action. The present study aimed to formulate and evaluate a topical antifungal gel of clotrimazole using a combination of natural and synthetic excipients to enhance safety, spreadability, and drug release. Gels were prepared using natural gelling agents such as tragacanth and gelatin, along with polyethylene glycol 400, glycerin, aloe vera, vitamin E, and benzoic acid as a preservative. The formulations were evaluated for physicochemical properties including pH, spreadability, viscosity, washability, homogeneity, drug content, and in vitro drug release using simulated vaginal fluid. Among the prepared formulations, batch F2 demonstrated optimal spreadability, acceptable viscosity, and superior drug release characteristics. The results indicate that clotrimazole gel formulated with natural excipients can serve as a safe, effective, and patient-friendly topical antifungal delivery system.

A Neuralink in the Pharmaceutical Field: A Comprehensive Review of Brain–Computer Interface Applications in Drug Development and Neurological Therapy

Fri, 24 Apr 2026 00:00:00 -0400

Recent developments in neurotechnology have created new possibilities for advancing biomedical and pharmaceutical research. One of the most promising innovations is the brain–computer interface (BCI), a technology that enables direct communication between the human brain and external computing systems. Neuralink, a neurotechnology company established by Elon Musk, is developing high-bandwidth implantable neural interfaces capable of both recording and stimulating brain activity. These devices use ultra-thin electrode threads implanted into the brain to capture neuronal signals and transmit them wirelessly to computers for analysis. Such technology has significant implications for pharmaceutical science, particularly in areas such as neurological drug discovery, personalized treatment strategies, and real-time therapeutic monitoring. By providing continuous observation of neural responses to medications, Neuralink may accelerate the development of new drugs, enhance clinical trial evaluation, and support precision medicine approaches for neurological conditions including Parkinson’s disease, epilepsy, major depressive disorder, and Alzheimer’s disease. This review paper analyzes the technological principles behind Neuralink systems and discusses their potential applications in pharmaceutical research. Additionally, it evaluates the benefits, challenges, ethical considerations, and future research directions associated with integrating brain–computer interface technology into pharmaceutical development.

Eosinophilia: A Comprehensive Review For Pharmacy Practice

Thu, 30 Apr 2026 00:00:00 -0400

Eosinophilia is defined as an elevated eosinophil count in the peripheral blood and is often associated with a wide range of clinical conditions. This review discusses the aetiology, classification, and pathophysiological mechanisms of eosinophilia, with special attention to diseases such as eosinophilic granulomatosis with polyangiitis (EGPA), eosinophilic esophagitis (EoE), and paediatric eosinophilia. Diagnostic approaches, treatment strategies, and implications for pharmacy practice are also explored. A comprehensive understanding of eosinophilia is vital for accurate diagnosis, targeted therapy, and effective patient counselling.

Emerging Perspectives on Latent Autoimmune Diabetes in Adults: A Distinct Diabetes Mellitus Variant

Wed, 06 May 2026 00:00:00 -0400

Latent Autoimmune Diabetes in Adults (LADA) is an autoimmune disease in which the immune system slowly attacks and destroys insulin-producing beta cells in the pancreas. It is different from Type 1 diabetes, which is generally due to the autoimmune destruction of insulin-producing cells, pancreatic beta cells, LADA variant in diabetes progresses more gradually and often intensify later in life. This slower onset mimics Type 2 diabetes mellitus, differentiating it from other diabetes mellitus forms. LADA comprises features of both Type 1 and Type 2 diabetes, which apparently leads to misdiagnosis as Type 2 in its early phases. As the disease progresses, pancreatic insulin production declines consistently, emphasize the value of accurate diagnosis and personalized management to prevent various serious complications. Research shows that about 10% of individuals initially diagnosed with Type 2 diabetes actually have LADA, it is traceable by circulating islet autoantibodies. These patients poorly respond to oral medications like sulfonylureas- Glimepiride, Glipizide. LADA identification is pivotal for improving effective treatment, though it remains challenging due to limited directions for antibody screening in adult-onset cases. Greater knowledgeon LADA enhances its clinical handling and increases awareness on the broader spectrum of autoimmune diabetes and about it’s different variants like- Type 1 diabetes, Type 2 diabetes mellitus, Gestational diabetes, Type 5 diabetes, MODY- Maturity onset diabetes in young.